Tests an AI tool with ultrasound and contrast to detect prostate cancer
Tests an AI ultrasound method for finding significant prostate cancer in adult men.
Plain-language title generated from the registry record
Registry title: TULIP ReTrain Study
Key facts
- Where
- Amsterdam, NetherlandsSee the site
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Trial code
- NCT06974539
- Record updated
- 16 May 2025
- Original description
This prospective clinical study aims to retrain and validate the PCaVision AI algorithm for the detection and localization of clinically significant prostate cancer (csPCa) using multiparametric ultrasound (mpUS) with two different ultrasound contrast agents: Sonovue and Optison. Data will be collected using a commercial version of the LOGIQ E10 ultrasound machine, with full histopathological correlation in patients undergoing radical prostatectomy.Read full original descriptionShow less
Optimization of PCaVision: A Prospective Study for CAD-based Detection of Clinically Significant Prostate Cancer Using mpUS and Contrast Agents
This prospective clinical study aims to retrain and validate the PCaVision AI algorithm for the detection and localization of clinically significant prostate cancer (csPCa) using multiparametric ultrasound (mpUS) with two different ultrasound contrast agents: Sonovue and Optison. Data will be collected using a commercial version of the LOGIQ E10 ultrasound machine, with full histopathological correlation in patients undergoing radical prostatectomy.
Inclusion: Male ≥18 years; Cohort 1: Histologically confirmed prostate cancer scheduled for radical prostatectomy; Cohort 2: Negative multiparametric prostate MRI (PI-RADS ≤ 2).
Exclusion: Severe pulmonary hypertension; Cardiac right-to-left shunt; Known allergy to Sonovue or Optison; Contraindication for ultrasound contrast agents.